

ASX ANNOUNCEMENT

15 November 2024

Supplementary Scheme Booklet Dispatched

Anteris Technologies Ltd (ASX: AVR) (**ATL** or the **Company**) refers to its announcement made on 12 November 2024 that the Supreme Court of Queensland had approved the convening of the deferred Scheme Meetings and the distribution of the supplementary scheme booklet (**Supplementary Scheme Booklet**) in relation to the share and option schemes of arrangement between ATL and its shareholders (**Share Scheme**) and ATL and its optionholders (**Option Scheme**, and together with the Share Scheme, the **Schemes**).

Dispatch of Supplementary Scheme Booklet

The Company confirms that on Friday 15 November 2024, the Supplementary Scheme Booklet and associated materials were dispatched to ATL shareholders and ATL optionholders as follows:

- ATL shareholders and ATL optionholders who had previously elected to receive electronic communications from the Company were sent an email containing instructions regarding how to view or download a copy of the Supplementary Scheme Booklet;
- ATL shareholders and ATL optionholders who had previously elected to receive only hard-copy documents from the Company were sent, via post to their registered address, a hard copy of the Supplementary Scheme Booklet; and
- ATL shareholders and ATL optionholders who had made no election as to how to receive communications from the Company were sent a letter, sent via post to their registered address, containing instructions regarding accessing a copy of the Supplementary Scheme Booklet

The Scheme Booklet, including the Independent Expert's Report, and the Supplementary Scheme Booklet, are available for viewing and download on ATL's website www.anteristech.com.

Details of Scheme Meetings and Extraordinary General Meeting

The Scheme Meetings will be held on Tuesday, 3 December 2024 at the Hotel Grand Chancellor Brisbane, 23 Leichhardt Street, Spring Hill QLD 4000 or virtually via an online platform at the relevant link below:

- Share Scheme Meeting – <https://meetnow.global/MQVUPQJ>; and
- Option Scheme Meeting – <https://meetnow.global/MY6QYUR>.

On Tuesday, 3 December 2024, immediately prior to the Scheme Meetings, the Company will hold the Extraordinary General Meeting at the Hotel Grand Chancellor Brisbane, 23 Leichhardt Street, Spring Hill QLD 4000 or virtually via an online platform at the relevant link below:

- Extraordinary General Meeting - <https://meetnow.global/M4QMGH9>.

REGISTERED OFFICE

Toowong Tower, Level 3, Suite 302
9 Sherwood Road
Toowong, QLD 4066
Australia



BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

T: +61 1300 550 310
info.au@anteristech.com
anteristech.com

The Extraordinary General Meeting will commence at 10:00 am (AEST) / 11:00 am (AEDT). The Share Scheme Meeting will commence at the later of 10:30 am (AEST) / 11:30 am (AEDT) and the conclusion of the Extraordinary General Meeting and the Option Scheme Meeting will commence at the later of 11:00 am (AEST) / 12:00 pm (AEDT) and the conclusion of the Share Scheme Meeting.

All ATL shareholders and ATL optionholders registered as at 6:00 pm (AEST) / 7:00 pm (AEDT) on 1 December 2024 will be eligible to vote at, with respect to ATL shareholders, the Extraordinary General Meeting and Share Scheme Meeting and, with respect to ATL optionholders, the Option Scheme Meeting.

Voting

All ATL shareholders and ATL optionholders are encouraged to vote by attending the Extraordinary General Meeting and Scheme Meetings, as relevant, in person or by attorney or corporate representative, or alternatively by completing and ensuring the relevant proxy form which accompanied the Scheme Booklet is received by ATL's share registry by 10:00 am (AEST) / 11:00 am (AEDT) on 1 December 2024 for the Extraordinary General Meeting, by 10:30 am (AEST) / 11:30 am (AEDT) on 1 December 2024 for the Share Scheme Meeting or by 11:00 am (AEST) / 12:00 pm (AEDT) on 1 December 2024 for the Option Scheme Meeting.

If you have already voted

Despite the revisions to the timetable for the Schemes, Proxy Forms which have been validly submitted by ATL shareholders or ATL optionholders at the date of the Supplementary Scheme Booklet will be deemed valid for the Scheme Meetings and the Extraordinary General Meeting, unless withdrawn or revoked.

ATL shareholders or ATL optionholders which have already directed their proxy how to vote at the Scheme Meetings or Extraordinary General Meeting may change that direction by submitting a new Proxy Form. If a new Proxy Form is validly submitted to the Share Registry, it will be taken to revoke any previously submitted Proxy Form by that ATL shareholder or ATL optionholder.

Further information

Further information on, and information regarding how to participate in, the Extraordinary General Meeting and the Scheme Meetings was provided in the notices of meeting for the Extraordinary General Meeting and the Scheme Meetings included in the Scheme Booklet. If ATL shareholders or ATL optionholders have additional questions about the Scheme Booklet, the Supplementary Scheme Booklet or the Schemes, including to request a new Proxy Form, please contact the ATL Schemes Information Line on 1300 264 812 (within Australia) or +61 3 9415 4634 (outside Australia) Monday to Friday between 7:30 am and 4:00 pm (AEST) / 8:30 am and 5:00 pm (AEDT)

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR®, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR® THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.



DurAVR® THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR® Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR® THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech

